Fig. 5

A Sphere formation assays were performed on the control group and L-741626-treated Huh7 and HepG2 cell lines, and the sphere formation rate was calculated (scale bar: 50 μm). B Spheres from both the control and L-741626-treated groups were collected, and proteins were extracted for Western blot analysis to assess the expression levels of the tumor stemness marker CD133. C Schematic diagram of the construction and treatment of the Huh7 tumour-bearing mouse model. D Tumour tissue images from different treatment groups on Day 19 (n = 5). E Changes in tumour volume across each treatment group during the treatment period. F Tumour weights in different treatment groups. G Tumour inhibition rates of Huh7 tumour-bearing mice in each treatment group. The data are presented as means ± SDs; * P < 0.05; ** P < 0.01; ***P < 0.001